UY27673A1 - Procedimiento para la preparación de un producto de inhalación en polvo que contiene una sal del antagonista de cgrp, - Google Patents

Procedimiento para la preparación de un producto de inhalación en polvo que contiene una sal del antagonista de cgrp,

Info

Publication number
UY27673A1
UY27673A1 UY27673A UY27673A UY27673A1 UY 27673 A1 UY27673 A1 UY 27673A1 UY 27673 A UY27673 A UY 27673A UY 27673 A UY27673 A UY 27673A UY 27673 A1 UY27673 A1 UY 27673A1
Authority
UY
Uruguay
Prior art keywords
preparation
powder inhalation
salt
procedure
product containing
Prior art date
Application number
UY27673A
Other languages
English (en)
Inventor
Michael Trunk
Claudius Weiler
Original Assignee
Boehringer Ingelheim Pharma
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY27673A1 publication Critical patent/UY27673A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invención se refiere a sales de la base de principio activo 1-(N2 -(3,5 -dibrono-N- (dihidro 2 (1H) -exoquinazolin- 3-il) 1-piperidinil) carbonil) -D-tirosil)- L ) lisil )-(4 piridinil) - piperazina (BIBN4096) de la fórmula I, a su preparación, a un procedimiento para la preparación de un producto de inhalación en polvo que contiene una sal del principio activo BIBN4096, así como a los productos de inhalación en polvo obtenibles mediante el procedimiento.
UY27673A 2002-02-19 2003-02-17 Procedimiento para la preparación de un producto de inhalación en polvo que contiene una sal del antagonista de cgrp, UY27673A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10206770A DE10206770A1 (de) 2002-02-19 2002-02-19 Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096

Publications (1)

Publication Number Publication Date
UY27673A1 true UY27673A1 (es) 2003-09-30

Family

ID=27635111

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27673A UY27673A1 (es) 2002-02-19 2003-02-17 Procedimiento para la preparación de un producto de inhalación en polvo que contiene una sal del antagonista de cgrp,

Country Status (12)

Country Link
EP (1) EP1478382B1 (es)
JP (1) JP4085064B2 (es)
AR (1) AR038571A1 (es)
AT (1) ATE347900T1 (es)
AU (1) AU2003208853A1 (es)
CA (1) CA2476711A1 (es)
DE (2) DE10206770A1 (es)
ES (1) ES2279094T3 (es)
PE (1) PE20030931A1 (es)
TW (1) TW200400184A (es)
UY (1) UY27673A1 (es)
WO (1) WO2003070753A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10314617A1 (de) * 2003-04-01 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018795A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59711622D1 (de) * 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
DE19937304C2 (de) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
PT1666028E (pt) * 1999-10-29 2010-06-15 Novartis Ag Composições de pós anidros com melhor dispersividade

Also Published As

Publication number Publication date
EP1478382A1 (de) 2004-11-24
JP4085064B2 (ja) 2008-04-30
TW200400184A (en) 2004-01-01
DE10206770A1 (de) 2003-08-28
DE50305954D1 (de) 2007-01-25
EP1478382B1 (de) 2006-12-13
WO2003070753A1 (de) 2003-08-28
ES2279094T3 (es) 2007-08-16
ATE347900T1 (de) 2007-01-15
PE20030931A1 (es) 2003-12-18
AR038571A1 (es) 2005-01-19
JP2005538934A (ja) 2005-12-22
AU2003208853A1 (en) 2003-09-09
CA2476711A1 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
UY27673A1 (es) Procedimiento para la preparación de un producto de inhalación en polvo que contiene una sal del antagonista de cgrp,
CY1119261T1 (el) Παραγωγα θειαζολιου
CR11482A (es) Derivados de 1,2,3-triazol para uso como inhibidores de estearoil-coenzima a desaturasa
ECSP055853A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
HRP20040686B1 (hr) Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza
GT200600496A (es) Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea.
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
PA8591701A1 (es) Derivados de pirrolopirimidina
UY30888A1 (es) Procedimiento
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
AR056860A1 (es) Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores
PA8586501A1 (es) Tabletas dispersables que comprenden un derivado de acido benzoico
GT200500309A (es) Derivados de sulfonilbencilimidazol
MX2019006843A (es) Inhibidor de cdk4/6.
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
WO2008074833A3 (en) Compounds
AR126052A1 (es) Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos
ECSP024374A (es) Derivados del 4,5-dihidro-tiazol-2-ylamina y sus usos como inhibidores de no sintetasa
UY30556A1 (es) Derivados 2, 7-sustituidos de 4-(3-metilmorfolin-4-il)pirido[2,3-d]pirimidinas y sales farmacéuticamente aceptables de los mismos, composiciones farmacéuticas y aplicaciones
TH70149A (th) ยาเม็ดที่บรรจุยาสูง
ECSP992966A (es) Compuestos de amindazol
TH102392A (th) การดำเนินการให้ของสารยับยั้งไดเปปติดิล เปปติเดส

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126